Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S086 Tablets in Mild to Moderate Primary Hypertension (Phase II)
CTR20200359Phase 2Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of S086 in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started Jun 2020; status: completed.
02
Drugs
S086
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20200359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200359.